

Supplementary Table 1. Baseline characteristics of patients according to participating clinical trials

Characteristic	GO-BEFORE (n = 30)	GO-FORWARD (n = 30)	p value
Age, yr	55.5 (43.8–62.5)	49.5 (42.8–55.5)	0.10
Female sex	26 (86.7)	29 (96.7)	0.35
Disease duration, yr	7.5 (6.4–9.9)	14.9 (10.7–20.3)	< 0.01
DAS28 remission	14 (46.7)	16 (53.3)	0.61
Positive rheumatoid factor	21 (70.0)	23 (76.7)	0.13
Positive anti-CCP Ab	18 (60.0)	14 (46.7)	0.30
Swollen joint count (0–28)	0.5 (0.0–2.0)	1.0 (0.0–2.0)	0.94
Tender joint count (0–28)	1.0 (0.0–4.0)	0.0 (0.0–2.3)	0.35
Patient's global assessment (0–10)	2.7 (1.4–5.7)	2.8 (1.3–5.5)	0.74
Physician's global assessment (0–10)	1.2 (0.4–2.7)	1.6 (0.4–2.9)	0.88
HAQ (0–3)	0.8 (0.1–1.5)	0.4 (0.0–1.3)	0.19
CRP, mg/dL	0.3 (0.3–0.3)	0.3 (0.3–0.3)	0.24
ESR, mm/hr	23.0 (9.8–42.5)	37.0 (24.5–44.5)	0.04
DAS28-CRP	3.1 (1.9–3.7)	2.3 (1.8–3.2)	0.24
DAS28-ESR	3.4 (2.7–4.4)	3.1 (2.8–4.1)	0.76
Pain score (0–10)	2.7 (1.1–6.2)	2.5 (1.1–5.9)	0.65
Patients with bone erosion	15 (50.0)	23 (76.7)	0.08
Patients with joint space narrowing	7 (23.3)	23 (76.7)	< 0.01
Concomitant cDMARD			0.03
MTX monotherapy	28 (93.3)	20 (66.7)	
MTX + cDMARD	2 (6.7)	6 (20.0)	
No cDMARD	0	4 (13.3)	
Corticosteroid	19 (63.3)	15 (50.0)	0.30

Values are presented as median (interquartile range) or number (%).

DAS, disease activity score; CCP Ab, cyclic citrullinated peptide antibody; HAQ, Health Assessment Questionnaire; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; cDMARD, conventional disease modifying antirheumatic drug; MTX, methotrexate.